Switching Crohn’s patients to biosimilar Inflectra from Remicade is safe and effective, Pfizer says
pharmafile | October 30, 2017 | News story | Research and Development, Sales and Marketing | Crohn’s disease, Pfizer, Remicade, crohn’s disease, inflectra, pharma
Pfizer has released new data on its Crohn’s disease (CD) treatment Inflectra (infliximab CT-P13) which indicate that switching patients to the drug from Remicade (infliximab) is comparably safe and effective to treatment with Remicade alone over a 24-week period.
Trials comparing the two therapies lasted 54 weeks in total, and results from this complete period in biologic-naïve patients with active CD indicated “the long-term effectiveness of treatment with CT-P13”, the company said in a statement.
“These new data add to the considerable body of evidence, including real-world studies and the NOR-SWITCH trial, for the switching of stable patients to CT-P13,” commented Sam Azoulay, Senior Vice President and Chief Medical Officer at Pfizer Essential Health. “Today’s announcement further highlights Pfizer’s commitment to biosimilars and provides additional evidence supporting use of CT-P13 in Crohn’s disease.”
The results were revealed by Pfizer alongside Cellitron Healthcare at the 25th United European Gastroenterology (UEG) Week.
“The data announced today show that 24 weeks (six months) after switching from infliximab to the infliximab biosimilar CT-P13, patients with Crohn’s disease continue to experience similar efficacy, safety and tolerability compared to staying on infliximab,” explained Stephen B Hanauer, Professor of Medicine, Gastroenterology and Hepatology, at the Feinberg School of Medicine, Northwestern University. “These data support previous findings which demonstrate the importance of CT-P13 as a treatment option for patients with Crohn’s disease, providing healthcare professionals further confidence when stable patients switch to CT-P13 from infliximab.”
Matt Fellows
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Polpharma Biologics and Fresenius Kabi partner to develop treatment for ulcerative colitis and Crohn’s disease
Polpharma Biologics has signed a global licensing agreement with Fresenius Kabi for the commercialisation of …
A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK
By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in …
